お知らせ • Aug 05
Izotropic's Izoview Positioned to Capitalize on Key Global Breast Imaging Market Drivers
Izotropic Corporation has led to an increase in supplemental imaging, particularly with ultrasound and contrast-enhanced modalities, for women whose cancers are more likely to be missed by mammography alone, which fails to detect approximately 20% of breast cancers present at the time of screening. In response, governments and payers are adjusting policy frameworks to support early detection initiatives. In the U.S., Food and Drug Administration ("FDA")-mandated regulations now require providers to inform patients of their breast density, and 38 states have mandated insurance coverage for supplemental screening. Similar policy developments are occurring globally. These enhancements are also helping to compensate for known limitations in current technologies, offering a layer of analytical assistance to help streamline the diagnostic process. Since the beginning of 2025 alone, the FDA has approved over 100 AI algorithms in radiology, underscoring the pace of validation and integration of these technologies into clinical practice. AI-powered systems further facilitate predictive analytics, allowing providers to assess individualized cancer risk by integrating genetic data, imaging findings, and clinical history. However, the effectiveness of these algorithms relies heavily on the quality of the imaging data used for training and application, reinforcing the critical need for high-resolution, three-dimensional modalities capable of capturing the anatomical detail required for robust AI analysis. As imaging centers modernize, AI is becoming an essential component of new breast imaging systems, elevating performance while optimizing resources. The projected growth across imaging modalities clearly reflects the impact of these converging trends. In clinical scenarios such as high-risk screening, where MRI is currently the preferred modality, IzoView offers potential advantages, including spatial image resolution approximately 100x greater than MRI. Clinical trials conducted at UC Davis Medical Center, where the foundational breast CT technology was developed and for which IzoView holds the exclusive global rights, have demonstrated that the diagnostic performance of contrast-enhanced breast CT is comparable to MRI, and have suggested that contrast-enhanced breast CT may enable more accurate margin analysis, improved lesion characterization, and superior visualization of microcalcifications. IzoView is engineered to align with the shift toward personalized imaging and individualized screening protocols. IzoView's intellectual property portfolio is strategically layered, securing the platform across its most commercially and clinically significant dimensions. IzoView extends beyond imaging hardware to include integrated capabilities such as image acquisition, data presentation, system usability, radiation safety, and workflow integration, reflecting IzoView's potential as a complete breast health solution. The portfolio includes foundational patents and new filings, with protections extending into the 2040s, as well as key innovations like Izotropic's proprietary deep machine-learning reconstruction algorithm, held as a trade secret. IzoView is uniquely positioned to support 14 potential future Indications for Use in its current form, across five key areas of breast health: screening, diagnosis, monitoring, planning, and personalized medicine. Many of these expanded indications can be enabled with new clinical studies and delivered through software upgrades, allowing early adopters to increase IzoView's clinical utility without replacing the core system, supporting long-term expansion, platform extensibility, and a recurring revenue model. IzoView is also uniquely equipped to support the integration of artificial intelligence into breast imaging workflows- a market driver accelerating clinical adoption across the radiology landscape. Unlike modalities constrained by compression-induced distortion or variable operator skill levels, IzoView's true 3D data acquisition can provide the consistency and anatomical detail necessary to unlock the full potential of AI applications. This positions IzoView as a data-rich platform aligned with the evolving direction of radiology: toward predictive analytics, and a recurring revenue model; and IzoView is also uniquelyequipped to support the integration of artificial Intelligence into breast imaging workflows - a market driver accelerate clinical adoption across the radiology environment. Unlike modalities constrained by compressed-induced distortion or variable operator skills, IzoView's true3D data acquisition can provide the consistent and anatomical detail necessary to unlock The full potential of AI applications.